In the context of the global carbon neutrality strategy, syngas fermentation technology has emerged as a research hotspot in biomanufacturing because it can recover and convert industrial exhaust gas. Relying on the Wood-Ljungdahl pathway in acetogens, this technology converts gaseous substrates, such as CO and CO2, into high-value-added chemicals. However, bottlenecks including low gas-liquid mass-transfer efficiency and challenges with scale-up, severely limit its industrialization. The review focuses on core research-level topics, including the key enzymatic mechanisms of acetogens, metabolic regulation strategies, and high-throughput strain construction technologies; systematically analyzes the feed gas pretreatment process, design principles of large-scale reactors, fermentation process optimization, efficient product separation and purification technologies, and full-process integration at the process level; and summarizes techno-economic analysis and global policy support for industrial application. Finally, it thoroughly analyzes the core challenges of this technology across core mechanisms, engineering operations, economic markets, and industrial chain coordination, and outlines the future development direction of the technology. By systematically collating the syngas fermentation technology system and its industrialization bottlenecks, this review provides references for its industrialization. It is positioned to boost the economic viability and industrial appeal of the CCUS system, acting as a pivotal engine for advancing deep industrial decarbonization and fostering emerging green industries.
Rapid advances in CRISPR/Cas systems and the growing global demand for rapid, accurate diagnostics underscore the necessity of reviewing how these technologies are transforming molecular testing. Conventional diagnostic approaches are frequently constrained by prolonged turnaround times, complex instrumentation, and limited analytical sensitivity, and these limitations were starkly highlighted during the COVID-19 pandemic. In this context, we present a comprehensive and timely overview of CRISPR/Cas-based molecular diagnostics. We begin by summarizing the classification and molecular mechanisms of CRISPR/Cas types I–VI, followed by a detailed discussion of innovative detection strategies such as SHERLOCK, DETECTR, and amplification-free platforms that significantly enhance analytical sensitivity and specificity. We further explore clinical applications across infectious disease surveillance, antimicrobial resistance profiling, early cancer detection, genetic variant identification, and the emerging detection of non-nucleic acid biomarkers. Finally, we discuss future perspectives, including the development of miniaturized, high-throughput, and AI-assisted diagnostic platforms, their integration with microfluidics and portable readout systems for point-of-care applications, and highlight critical challenges such as standardization, automation, and cost-effectiveness that must be addressed to facilitate clinical translation.
